Medical University of Graz, Graz, Austria.
Biomark Med. 2010 Dec;4(6):895-903. doi: 10.2217/bmm.10.104.
In recent years, biobanks of human tissues have evolved from small-scale collections of pathological materials into structured resource centers for acquisition, storage, processing and usage of high-quality biospecimens for research. This evolution goes hand in hand with the development of highly sensitive, high-throughput methods for biomarker discovery. The complexity of the molecular patterns of diseases such as cancer provides multiple opportunities for targeted therapeutic intervention, tailored to suit the particular characteristics of each patient. Developing and evaluating such novel therapies requires access to rigorously designed and well-structured collections of biospecimens. In turn, biobanking infrastructures have a critical impact on the discovery, development and implementation of new drugs for cancer treatment. Therefore, it is essential to harmonize biobanking procedures, and to develop innovative solutions supporting biobank interoperability and specimen sharing, ensuring that new drugs may effectively reach out to the largest possible number of patients.
近年来，人体组织生物库已从规模较小的病理材料收集发展成为获取、存储、处理和使用高质量生物样本的结构化资源中心，用于研究。这种发展伴随着高灵敏度、高通量生物标志物发现方法的发展而同步进行。癌症等疾病的分子模式的复杂性为靶向治疗干预提供了多个机会，可根据每个患者的特定特征进行定制。开发和评估此类新型疗法需要严格设计和结构良好的生物样本集。反过来，生物库基础设施对癌症治疗新药的发现、开发和实施具有关键影响。因此，协调生物库程序并开发支持生物库互操作性和标本共享的创新解决方案至关重要，以确保新药物能够有效地惠及尽可能多的患者。
